# **STOCK OF THE WEEK**

# YATHARTH HOSPITAL & TRAUMA CARE SERVICES LTD.

Sector

Healthcare

Sep 23, 2024

# Buy at CMP: Rs 560 | Target: Rs 660 (18%) | SL: Rs 515

Yatharth Hospital operates three super specialty hospitals in Delhi NCR, offering advanced healthcare services. All hospitals are NABH accredited, with two also NABL accredited. They provide modern suites, spacious rooms, and comfortable patient areas. The hospitals are equipped with state-of-the-art medical equipment like Azurion catheter labs, MRI, CT scans, and advanced surgical tools.

## **Investment Rationale**

- Increase in high value specialties mix led to better growth in ARPOB: In Q1FY25 Yatharth has touch INR 30,551 ARPOB. AR-POB grew by 10% CAGR from FY21 to FY24 (INR 21,286.74 to INR 28,571) the growth was driven by increase in share of high value specialty mix across hospital. In FY21 56% of revenue was contributed by internal Medicine, In Q1FY25 Internal Medicine contribute 23%, Neurosciences 11% from 6.27%, oncology 10% from 4%, Cardiology 9% from 7.14%. This strategic shift toward super-specialty and specialty has led to better growth in ARPOB, improved the occupancy rate and increase the patient footfall. The management's focus on oncology, nephrology, cardiology, and pulmonology this change the specialty mix and will drive ARPOB going ahead. We expect ARPOB to grow by 9% CAGR from FY24 to FY27.
- Strong bed addition will continue the growth trajectory in Yatharth: The company plans to expand its bed capacity from 1,605 in Q1 FY25 to 2,800-3,000 by FY28, with a capex of INR 65 lakh per bed. The expansion includes both greenfield and brownfield projects. It recently acquired a 200-bed hospital in Faridabad and announced 200 and 250-bed expansions at its Greater Noida and Noida facilities by FY27. Management aims to add at least one hospital annually in the next few years, boosting bed capacity by 46% by FY27. ICU beds, which rose from 17% in FY21 to 32% in FY24, are expected to further increase, improving ARPOB and margins.
- Strong Balance Sheet support organic and inorganic growth initiatives: The company reduced its debt by 68% from INR 267 Cr to INR 85 Cr in FY24 using IPO proceeds and is now net debt-free. The fall in debts will led to fall in finance cost, this will improve the PAT growth coupled with EBITDA growth company is well poised for capex plan. YATHARTH cash is 23% of the balance sheet, which was 10% in FY21. This improved the liquidity and support the capex plan.
- Outlook and Valuations: We model a Revenue/PAT CAGR of 35%/26% and estimate YATHARTH to clock PAT of Rs 251 Cr by FY27E. YATHARTH is trading at forward EV/EBITDA (x) of 15 and we value at 19(x) FY27E and Recommend BUY on YATHARTH with Target Price of Rs. 660 (18%).

# **Financial Snapshot**

Year	Revenue	EBITDA	ΡΑΤ	PE Ratio (x)	EV/EBITDA (x)
FY24	728	51	126	38.2	22.1
FY25E	982	265	138	35.0	66.1
FY26E	1,326	358	186	25.9	49.0
FY27E	1,790	483	251	19.2	36.3

Source: Company Data, Ace Equity, GEPL Research

Script Details	
BSE Group	В
BSE Code	543950
NSE Code	YATHARTH
Bloomberg Code	YATHARTH IN
Market Cap (INR Cr.)	4,808
Free Float (%)	33.5%
52wk Low/High	597/344
Beta (1yr Nifty 50)	0.00
Face Value (INR)/ D. Yield (%)	10/0
Total paid Up Shares (Mn.)	85.9

Share Holding Pattern (%)					
Promoters	Public	Others			
66.5%	33.5%	-			

# Share Price Relative Performance





# **TECHNICAL VIEW**

### Observation

- Since its breakout above the March 2024 swing high in August 2024, the stock has consistently demonstrated strong upward price action, reinforcing a positive outlook. This breakout marked a significant shift, propelling the stock into a phase of continued bullish momentum.
- On the daily scale, the stock has maintained a clear structure of higher tops and higher bottoms, which is a hallmark of a strong and sustained uptrend. This formation suggests that each upward movement is followed by a minor dip, but the stock continues to climb to new highs after each pullback. These minor dips have been healthy corrections within the larger rising trend, during which the stock has reverted back to its 12-day and 26-day EMAs. This bullish mean reversion—where price dips find support at key moving averages—signals strength and the likelihood of further upward movement.
- From a momentum perspective, the MACD indicator remains in buy mode, reflecting the strong bullish sentiment. Importantly, the histogram, which measures the distance between the MACD line and its signal line, has been rising for five consecutive bars.
- Together, the combination of positive price structure, bullish mean reversion, and strengthening momentum indicated by the MACD reinforces the stock's upward trajectory. It suggests that the stock is poised to continue its rally, with both technical patterns and indicators aligning in favor of further gains.





## Inference & Expectations

- Considering these factors, it can be inferred that YATHARTH stock is set to continue uptrend.
- Going ahead we expect the prices to move higher till 660 level.
- The stop loss must be at 515 level, strictly on the closing basis.

Source: Tradingview.in, GEPL Research





Name	Designation	Email	Contact
Mr. Vidnyan Sawant	AVP – Technical Research	Vidnyan@geplcapital.com	+91 (22) 48934000
Mr. Dibandu Maji	Research Analyst, Fundamental Desk	dibandumaji@geplcapital.com	+91 (22) 66142689
Mr. Neel Parekh	Research Associate, Technical Desk	neelparekh@geplcapital.com	+91 (22) 66182687

#### Terms & Conditions – For Investors

We, Research Analyst of GEPL Capital, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We, also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

#### Disclosure: -

This document has been prepared by Research Department of GEPL Capital Put. Ltd. (hereinafter referred to as GEPL Capital) and this report is for personal information of the selected recipient/s and does not construe to be any investment, recommendation, prospectus, offering circular or legal or taxation advice to you. This research neport does not constitute an offer, invitation or inducement to invest in securities or other investments and GEPL Capital is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your general information and should not be reproduced or redistributed to any other personal incomstances and, if necessary, seek professional advice. The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future refurses are not guaranteed and a loss of original capital may occur. GEPL Capital makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability or obligation with respect to, the fairness, accuracy, completeness or correctness of any information or update information contained herein. All investments including Future and Options are involving risks and investor should exercise prudence in making their investment decisions. The report should not be regarded by the recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report as object to change emy adversely affect the value, price or income of any security or related instrument mentioned in this report. The information contained in this report has been obtained from sources that are considered to eeliable. However, GEPL Capital has not independently verified the accuracy or completeness of the same. Neither GEPL Capital nor any of its affiliates, its directors or is employees accepts any responsibility of what

#### **Disclaimers in respect of jurisdiction:**

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such Distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject GEPL Capital its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently send or has reached any individual the same may be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published for any purposes without prior written approval of GEPL Capital.

#### Analyst Certification:

The views expressed in this research report reflect the personal views of the analyst(s) about the subject securities or issues. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months.

GEPL Capital Private Limited is a SEBI registered Research Analyst entity bearing SEBI Reg. No. "INH000000081" under SEBI (Research Analysts) Regulations, 2014.

Reg./Corp. Office: D-21 Dhanraj Mahal, CSM Marg, Colaba, Mumbai 400 001 Contact No +91 22 66182400

SEBI Reg. No. NSE/NSEF&O/CD - INB230993934, INF230993934 & INE230993934. BSE/BSE F&O- INB010993934 & INF010993934,

#### For more information visit us at: www.geplcapital.com

Disclaimer: Investments in securities market are subject to market risks, read all the related documents carefully before investing. Investors must make their own investment decisions based on their specific goals, financial position & risk appetite. The content provided herewith is purely for investor awareness only.